Member Info for JimiHendrix

They have access to a facility to drawdown at least £300k every month if they need it, so they'll have enough for many more months. They will however need to raise cash specifically for the FDA process once contracts finalised, though I anticipate that will have a highly positive effect on the share price considering the size of the US market and that the test really is in a league of it's own... with there being no competition at all.

They have had more cash since from their finance facility with Riverfort, small amount of cash from adoption and more from a tax credit. They need cash for FDA process but we're waiting for them to finalise contracts with US partners first which they're supposed to be updating us on early this year.

Yes there will be significant recurring revenue from RNR1 and even more from the stroke marker test... should get full NICE recommendation for that later this year, though in the meantime JC is confident he can sell it for educational/research purposes in Europe.

Loads more near term positive news!

Jamrock, the latest meeting is available on YT too now... https://www.youtube.com/watch?v=p0zyb3PE8E8&t=4s&ab_channel=InvestorMeetCompany

Just a few sells, it still looks strong comparing to previous weeks. I think the market is well aware of the anticipated news flow on several fronts, that could land any day now.

From the Q&A...

"We believe we can collect the data required over a 3 to 6 month period, however NICE have up to 3 years to give their approval. So coming to the main issue, if we get specialist commissioning we can then circumvent the main need for the approval and roll the test out across the NHS quickly. The approval helps us where we need to secure funding – i.e. prior to specialist commissioning."

Fortunately he works for Genedrive. Regarding getting specialist commissioning, he's doing the same thing they did whilst he was working at Roche. Talking to the right people that have control of the budgets rather than the clinical experts, and there is an acceptance that this product will get it. He's pushing to get it sooner rather than later.

I'll find it and post it shortly...

Incidentally though, this is the Specialist Commissioning bit...

"I'm going to continue with my progression around special commissioning, as I've said I've pretty much now got absolute 100% clarity it's happening, but my big driver now is to make sure this happens as quickly as possible, and I will continue to lobby and press and chase and harry the people that are the decision makers around that."

So the part you've mentioned about talking to people is specifically about the 'timing' rather than whether we're getting it or not.

It's not 3 years of data gathering actually, I did some digging and found that NICE ask for "up to 3 years" of real world data. James Cheek said they believe they can generate the data NICE require in 3 or 4 months.

That's the Saudi Arabia distributor :)

Specialist Commissioning is what we need to speed up NHS adoption, JC was very confident we'll get it and sooner rather than later.

He also said they can generate the data NICE require in 3 months which presumably would suggest we could have Nice's full recommendation around the beginning of next year. Funding for real world evidence generation for the NICE EVA technologies to achieve full NICE guidance is expected October.

So if that's the timeline for NICE that Specialist Commissioning can be expected long before that otherwise it wouldn't be worth getting.

Lol, massive upside from this price point though! The last time the chart looked similar to this was December and we reached 12p.

People possibly taking positions before the anticipated Sussex, Surrey and Kent adoption Q1 ...and FDA partners update (expecting early this year so due an update any day now).

Also there seems to be many articles being published online on a regular basis now, about Genedrive and particular MT-RNR1 that there's bound to be an increasing and more sustained interest in the stock.

Powerhouse are not funding it…

“ Powerhouse will not be required to contribute any capital for these projects. Instead, the collaboration will be based on a license fee and royalties model. This arrangement establishes a long-term relationship between Powerhouse and National H2, while also potentially providing a long-term income stream for the Group.”

Yes indeed Basil! You’re referring to ‘specialist commissioning’ …the presentation and a very interest Q&A (that was published later) is still available on the Investor Meet website.

He said he has 100% clarification that it’s going to happen.

Rollout to Surrey, Kent and Sussex is also expected before the end of March and an announcement regarding FDA partners.

The market will be in for a pleasant surprise soon in that case.

I expect they sold a few yesterday and are talking it down hoping to buy back in cheaper. The trouble is it only takes 2 or 3 reasonable size buys and the ASK shoots up 10% or more. It could really shoot up from this point on any sustained buying.

It has nothing to do with Nice. It’s not a flaw that has been found, it is simply that a small batch of tests were stored incorrectly, in environment too hot. The documentation for the tests is extremely thorough and clearly describes the max and min temperature conditions that the test must be stored within to retain integrity, as with all medical devices and tests.

That’s absolute nonsense Roger lol

Yes exactly, it sounds like it almost certainly happened whilst in transport by the way it was described. Hospitals know very well how to store the tests safely as do Genedrive and manufacturers of course and would have been picked up sooner if it had happened whilst with them.

Neonatal Hearing Screening Device Market is Projected to Hit US$ 68.5 Million at a 4.90% CAGR by 2034.

Mentions Genedrive RNR1 and NICE around paragraph 10…

https://www.openpr.com/news/3397965/neonatal-hearing-screening-device-market-is-projected-to-hit-us

It’s going to go ballistic when positive FDA news is announced. They must be almost ready with the FDA partners deal, JC said ‘early this year’ so has to be very soon.